FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385716993> ?p ?o ?g. }

• W4385716993 endingPage "4532" @default.
• W4385716993 startingPage "4521" @default.
• W4385716993 abstract "Hypoxia is a significant feature of many solid tumors and can activate hypoxia-inducible factor 1α (HIF-1α)/vascular epidermal growth factor (VEGF) signaling pathway, which is closely related to the occurrence and development of primary liver cancer (PLC). Silymarin (SM) had been used as a traditional liver protective drug for decades. Recent studies have found that SM has chemopreventive and chemosensitizing effects on multiple cancers. In this study, we investigated the effects of SM on HIF-1α/VEGF signaling in human hepatocellular carcinoma cells under hypoxia conditions.HepG2 and Hep3B cells were divided into different experimental groups according to different culture conditions (aerobic or anaerobic) and the concentration of SM in the culture medium. The cellular proliferation, migration, invasion, colony formation, and apoptosis were observed by using methyl thiazolyl tetrazolium (MTT) assay, cell migration assay, in vitro invasion assay, soft agar colony formation assay, and Annexin V apoptosis assay, respectively. The cellular expressions of HIF-1α and VEGF were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and western blot (WB) analyses.SM reduced cellular proliferation, migration, invasion, and colony formation, but induced apoptosis in HepG2 and Hep3B cells under hypoxia conditions. The half inhibitory concentrations (IC50) of SM on HepG2 and Hep3B cells were 58.46 and 75.13 umol/L, respectively. SM also suppressed cellular expressions of HIF-1α and VEGF in HepG2 and Hep3B cells under hypoxia conditions at the mRNA and protein levels. All these effects of SM were dose dependent.The inhibitory effect of SM on HepG2 and Hep3B cells under hypoxia is partially via downregulating HIF-1α/VEGF signaling, which may serve as a potential drug therapy target for liver cancer based on SM." @default.
• W4385716993 created "2023-08-11" @default.
• W4385716993 creator A5002163860 @default.
• W4385716993 creator A5002943746 @default.
• W4385716993 creator A5034227844 @default.
• W4385716993 creator A5038763827 @default.
• W4385716993 creator A5061817335 @default.
• W4385716993 date "2023-01-01" @default.
• W4385716993 modified "2023-09-25" @default.
• W4385716993 title "Silymarin suppresses proliferation of human hepatocellular carcinoma cells under hypoxia through downregulation of the HIF-1α/VEGF pathway." @default.
• W4385716993 cites W1537392423 @default.
• W4385716993 cites W1809990660 @default.
• W4385716993 cites W2005530360 @default.
• W4385716993 cites W2024892096 @default.
• W4385716993 cites W2030085966 @default.
• W4385716993 cites W2043834052 @default.
• W4385716993 cites W2052469687 @default.
• W4385716993 cites W2508195907 @default.
• W4385716993 cites W2743461224 @default.
• W4385716993 cites W2758351006 @default.
• W4385716993 cites W2783038028 @default.
• W4385716993 cites W2799474486 @default.
• W4385716993 cites W2944297957 @default.
• W4385716993 cites W2947541069 @default.
• W4385716993 cites W2982653531 @default.
• W4385716993 cites W3006488526 @default.
• W4385716993 cites W3015426489 @default.
• W4385716993 cites W3017767374 @default.
• W4385716993 cites W3020847820 @default.
• W4385716993 cites W3047396053 @default.
• W4385716993 cites W3082247928 @default.
• W4385716993 cites W3112669310 @default.
• W4385716993 cites W3123935773 @default.
• W4385716993 cites W3128646645 @default.
• W4385716993 cites W3165718866 @default.
• W4385716993 cites W3178403391 @default.
• W4385716993 cites W3182985107 @default.
• W4385716993 cites W3189657553 @default.
• W4385716993 cites W3212381895 @default.
• W4385716993 cites W4210367763 @default.
• W4385716993 cites W4210395777 @default.
• W4385716993 cites W4210645555 @default.
• W4385716993 cites W4285118295 @default.
• W4385716993 cites W4285719527 @default.
• W4385716993 cites W3006632073 @default.
• W4385716993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37560243" @default.
• W4385716993 hasPublicationYear "2023" @default.
• W4385716993 type Work @default.
• W4385716993 citedByCount "0" @default.
• W4385716993 crossrefType "journal-article" @default.
• W4385716993 hasAuthorship W4385716993A5002163860 @default.
• W4385716993 hasAuthorship W4385716993A5002943746 @default.
• W4385716993 hasAuthorship W4385716993A5034227844 @default.
• W4385716993 hasAuthorship W4385716993A5038763827 @default.
• W4385716993 hasAuthorship W4385716993A5061817335 @default.
• W4385716993 hasConcept C104317684 @default.
• W4385716993 hasConcept C121608353 @default.
• W4385716993 hasConcept C127561419 @default.
• W4385716993 hasConcept C153911025 @default.
• W4385716993 hasConcept C167734588 @default.
• W4385716993 hasConcept C178790620 @default.
• W4385716993 hasConcept C185592680 @default.
• W4385716993 hasConcept C190283241 @default.
• W4385716993 hasConcept C2776415932 @default.
• W4385716993 hasConcept C2777025900 @default.
• W4385716993 hasConcept C2778019345 @default.
• W4385716993 hasConcept C2780783641 @default.
• W4385716993 hasConcept C502942594 @default.
• W4385716993 hasConcept C540031477 @default.
• W4385716993 hasConcept C54355233 @default.
• W4385716993 hasConcept C55493867 @default.
• W4385716993 hasConcept C62112901 @default.
• W4385716993 hasConcept C7836513 @default.
• W4385716993 hasConcept C81885089 @default.
• W4385716993 hasConcept C86803240 @default.
• W4385716993 hasConcept C88634738 @default.
• W4385716993 hasConcept C96232424 @default.
• W4385716993 hasConceptScore W4385716993C104317684 @default.
• W4385716993 hasConceptScore W4385716993C121608353 @default.
• W4385716993 hasConceptScore W4385716993C127561419 @default.
• W4385716993 hasConceptScore W4385716993C153911025 @default.
• W4385716993 hasConceptScore W4385716993C167734588 @default.
• W4385716993 hasConceptScore W4385716993C178790620 @default.
• W4385716993 hasConceptScore W4385716993C185592680 @default.
• W4385716993 hasConceptScore W4385716993C190283241 @default.
• W4385716993 hasConceptScore W4385716993C2776415932 @default.
• W4385716993 hasConceptScore W4385716993C2777025900 @default.
• W4385716993 hasConceptScore W4385716993C2778019345 @default.
• W4385716993 hasConceptScore W4385716993C2780783641 @default.
• W4385716993 hasConceptScore W4385716993C502942594 @default.
• W4385716993 hasConceptScore W4385716993C540031477 @default.
• W4385716993 hasConceptScore W4385716993C54355233 @default.
• W4385716993 hasConceptScore W4385716993C55493867 @default.
• W4385716993 hasConceptScore W4385716993C62112901 @default.
• W4385716993 hasConceptScore W4385716993C7836513 @default.
• W4385716993 hasConceptScore W4385716993C81885089 @default.
• W4385716993 hasConceptScore W4385716993C86803240 @default.
• W4385716993 hasConceptScore W4385716993C88634738 @default.

• next